ruxolitinib + peginterferon alfa-2a

This combination therapy, often referred to as the RUXOPeg regimen, consists of the JAK1/JAK2 inhibitor ruxolitinib and the pegylated cytokine peginterferon alfa-2a. It was evaluated in a Phase 1/2 clinical trial (NCT02742324) sponsored by the French Innovative Leukemia Organisation (FILO) for the treatment of patients with primary or secondary myelofibrosis, including post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Ruxolitinib works by inhibiting the Janus kinase signaling pathway, which is often overactive in myeloproliferative neoplasms, while peginterferon alfa-2a exerts antiproliferative and immunomodulatory effects. The combination aims to improve clinical outcomes and potentially achieve molecular responses by targeting different aspects of the disease biology through synergistic mechanisms.

Brand names

JakafiJakaviPegasys

Other names

ruxolitinib and peg-interferon alpha-2aRUXOPeg regimen